Aussie CSL Rejects Fear H1N1 Virus Could Mutate Before Vaccine Done
This article was originally published in PharmAsia News
Executive SummaryAustralia's CSL sought to discount concerns that an H1N1 vaccine against the latest influenza virus would mutate before people can receive shots. A spokeswoman said vaccinations are to begin in Australia in a few weeks, and it is "very unlikely" the virus would be able to mutate that soon. She said the kind of mutation required to make a virus ineffective would require at least a year in circulation. Australia has ordered 10 million doses of CSL's H1N1 vaccine and the company already is making test batches for clinical trials. (Click here for more
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.